ARNA: Arena Pharmaceuticals, Inc. - Summary | Jitta

Arena Pharmaceuticals, Inc.

NASDAQ:ARNA

Notice
Stock data is unavailable or the company’s delisted.
Price
$99.99
Loss Chance
58.1%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (13)
Recent Business Performance (11)
Financial Strength (43)
Return to Shareholders (8)
Competitive Advantage (13)
Jitta Signs
Revenue and EarningEarning loss detected in 2021
Operating MarginDeclined
Recent Business PerformanceEarning decline 26.13% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
1.31
116.13%
2.00
242.70%
Biotechnology
5.54
31.11%
3.95
71.78%
4.75
91.65%
COMPANY DESCRIPTION
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company’s investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.